Bizarre Patents
A haircutting appliance comprises an enclosed housing having a hollow handle connecting the housing to a vacuum source to carry away cut hairs from a subject's head.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8158131 | Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immun... | 04/17/2012 |
| 8142795 | Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk vaccine compositions stabilized with these stabilizers, particularly dry vac... | 03/27/2012 |
| 8142794 | Hepatitis C virus vaccine The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid ... | 03/27/2012 |
| 8105609 | Flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids... | 01/31/2012 |
| 8071108 | Pestivirus mutant for use in a vaccine The present invention comprises new pestivirus mutants, characterized in that the mutants are based on a cp strain of the virus wherein part of the gene sequence encoding the Npro region is deleted, except that the deleted part does not encompass the coding sequence... | 12/06/2011 |
| 8039003 | Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant. ... | 10/18/2011 |
| 8029802 | Vaccines against Japanese encephalitis virus and West Nile virus The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines. ... | 10/04/2011 |
| 7981431 | Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use A consensus peptide sequence designed for domain III of the envelope proteins of four serotypes of dengue virus and used in a vaccine against multiple serotypes of dengue virus is disclosed. The vaccine is able to elicit cross-neutralization antibody responses again... | 07/19/2011 |
| 7968102 | Dengue chimeric viruses The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Feve... | 06/28/2011 |
| 7943148 | Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines Highly immunoreactive viral peptides are disclosed which are derived from the E protein of major groups of the Flavivirus genus by computational analyses. These peptides are used in reliable diagnostic methods for the detection and diagnosis of Flavivirus, detecting... | 05/17/2011 |
| 7858099 | Method for inducing an immunological response in an animal This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein ERNS is inactivated, methods of preparing, using and detecting these. ... | 12/28/2010 |
| 7854937 | Flavivirus fusion inhibitors The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which empl... | 12/21/2010 |
| RE41745 | Recombinant Venezuelan Equine Encephalitis virus vaccine A prophylactic or therapeutic vaccine for use in protecting mammals such as humans or animals against Venezelan Equine Encephalitis virus (VEE) is described. In particular, the vaccine comprises a recombinant virus such as a recombinant vaccinia virus which is able ... | 09/21/2010 |
| 7790181 | Live attenuated viral vaccines for Eastern Equine Encephalitis virus Live attenuated Eastern Equine Encephalitis (EEE) vaccines that outperform the PE-6 vaccine in mice aerosol challenged with >1,000×LD50. Candidates include four furin-cleavage deletion mutants and one E3 deletion mutant. Each vaccine provided protection in birds ag... | 09/07/2010 |
| 7785604 | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications The present invention relates to nine residue peptides (ApoptoM) from flavivirus M ectodomain able to modulate specifically the apoptotic activity of diverse flavivirus, to pharmaceutical composition comprising the same and their use for the treatment and/or the pre... | 08/31/2010 |
| 7767210 | RNA virus vaccines and methods The invention is a vaccine, and method of vaccination, against RNA viruses, including RNA viruses in the family Flaviviridae, which includes for example West Nile Virus, Yellow fever virus, Dengue fever virus, Hepatitis C virus, Pestiviruses, Bovine viral diarrhea v... | 08/03/2010 |
| 7754222 | Safe mutant viral vaccines The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or... | 07/13/2010 |
| 7722885 | Dengue virus mutant strain MBU 01-2002 The invention includes a genetic construct and a mutant dengue virus, designated as strain MBU 01-2002, which is a mutant dengue virus generated by genetic modification of the 13-amino acid sequence just proximal to the pr-M junction within the prM coding region of ... | 05/25/2010 |
| 7648706 | West nile DNA vaccine The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are fo... | 01/19/2010 |
| 7648705 | Methods for prevention or amelioration of West Nile encephalitis using a West Nile DNA vaccine The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are fo... | 01/19/2010 |
| 7641908 | Dengue serotype 2 attenuated strain The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises... | 01/05/2010 |
| 7641909 | Avirulent, immunogenic flavivirus chimeras Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the ... | 01/05/2010 |
| 7641907 | Dengue serotype 1 attenuated strain The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition w... | 01/05/2010 |
| 7632510 | Methods of inducing flavivirus immune responses through the administration of recombinant flaviviruses comprising an engineered japanese encephalitis virus signal sequence The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic ... | 12/15/2009 |
| 7572456 | Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating sympto... | 08/11/2009 |
| 7572455 | Vaccine comprising an attenuated pestivirus Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Erns and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation ... | 08/11/2009 |
| 7560118 | Attenuated dengue virus comprising mutations in the NS3 gene A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines. ... | 07/14/2009 |
| 7521058 | Non-spreading pestivirus The invention relates to vaccines used in the eradication or control of pestivirus infections, particularly those used in pigs or ruminants. The invention provides nucleic acid, pestivirus-like particles and a pestivirus vaccine, comprising the nucleic acid or parti... | 04/21/2009 |
| 7494660 | HCV NS3-NS4A protease resistance mutants The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. ... | 02/24/2009 |
| 7488486 | Pharmaceutical compositions and articles of manufacture useful in reversal of a clinical epiosode of an incurable disease and methods of use thereof A method of reversing a clinical episode of a disease which is generally considered incurable in a subject. The method includes providing an immune-globulin preparation containing a detectable titre of antibodies to the disease which is generally considered incurabl... | 02/10/2009 |
| 7482017 | Flavivirus variants having phenotypic variation and immunogenic compositions thereof The present invention concerns isolated attenuated flaviviruses , such as West Nile viruses, having modifications that provide phenotypic varation, particularly in comparison to a more virulent reference strains. The invention encompasses the isolated viruses and im... | 01/27/2009 |
| 7476390 | antigens The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immun... | 01/13/2009 |
| 7459163 | Infectious DNA as a vaccine against west nile and other flaviviruses A vaccine for West Nile virus that protects a subject against West Nile infection comprising an a pharmaceutically acceptable carrier and a therapeutically effective dose of an infectious agent selected from the group consisting of: a live attenuated infectious (+) ... | 12/02/2008 |
| 7445787 | Methods for preventing or ameliorating West Nile encephalitis The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are fo... | 11/04/2008 |
| 7442381 | Alphavirus replicons and helper constructs The present invention provides a recombinant nucleic acid comprising: a first nucleic acid sequence encoding a 5′ alphavirus replication recognition sequence; at least one second nucleic acid sequence encoding an alphavirus nonstructural protein; at least one alph... | 10/28/2008 |
| 7425337 | Alphavirus replicon vector systems The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication competent alphavirus particles, as determined by passage on cells in culture. T... | 09/16/2008 |
| 7419789 | Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN recept... | 09/02/2008 |
| 7417136 | Nucleic acid for prevention of flavivirus infection The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus | 08/26/2008 |
| 7416733 | Flavivirus fusion inhibitors The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which empl... | 08/26/2008 |
| 7390495 | Neurovirulent strain of the West Nile virus and uses thereof Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof. ... | 06/24/2008 |
